MX9803568A - Producto para inhibir la union de h. influenzae a celulas humanas. - Google Patents

Producto para inhibir la union de h. influenzae a celulas humanas.

Info

Publication number
MX9803568A
MX9803568A MX9803568A MX9803568A MX9803568A MX 9803568 A MX9803568 A MX 9803568A MX 9803568 A MX9803568 A MX 9803568A MX 9803568 A MX9803568 A MX 9803568A MX 9803568 A MX9803568 A MX 9803568A
Authority
MX
Mexico
Prior art keywords
product
influenzae
attachment
casein
beta
Prior art date
Application number
MX9803568A
Other languages
English (en)
Inventor
Pradip Mukerji
Jennifer Marie Thurmond
Lennart Hansson
Jennifer Harris Baxter
Robert George Hards
Amanda Eun-Yeong Leonard
Steven Neal Anderson
Linda Ann Harvey
Original Assignee
Abbott Laboraties
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboraties filed Critical Abbott Laboraties
Publication of MX9803568A publication Critical patent/MX9803568A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se provee un producto para inhibir la union de H. influenzae a células humanas, tales como células faríngeas, poniendo en contacto los bacilos con beta-caseína humana, recombinante, foforilada, que tiene por lo menos 3 grupos fosfato. El producto que contiene la beta-caseína humana, recombinante, foforilada puede ser un producto nutricional enteral líquido, tal como una formula infantil. El producto nutricional enteral puede ser utilizado para la prevencion y el tratamiento de otitis media en bebés. La beta-caseína humana, recombinante, fosforilada también puede ser administrada como una aspersion para la garganta o usarse en gotas para la nariz o una aspersion.
MX9803568A 1995-11-06 1998-05-06 Producto para inhibir la union de h. influenzae a celulas humanas. MX9803568A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55394195A 1995-11-06 1995-11-06

Publications (1)

Publication Number Publication Date
MX9803568A true MX9803568A (es) 1998-09-30

Family

ID=24211413

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9803568A MX9803568A (es) 1995-11-06 1998-05-06 Producto para inhibir la union de h. influenzae a celulas humanas.

Country Status (8)

Country Link
EP (1) EP0859629B1 (es)
JP (1) JP2000503319A (es)
AT (1) ATE246934T1 (es)
AU (1) AU1158197A (es)
CA (1) CA2234680A1 (es)
DE (1) DE69629487D1 (es)
MX (1) MX9803568A (es)
WO (1) WO1997026320A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968901A (en) * 1989-10-30 1999-10-19 Andersson; Bengt Antibacterial composition
AU7610496A (en) * 1995-11-06 1997-05-29 Abbott Laboratories A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE465109B (sv) * 1989-10-30 1991-07-29 Bengt Andersson Antibakteriell komposition
US5795611A (en) * 1989-12-20 1998-08-18 Slattery; Charles W. Human infant formulas containing recombinant human alpha-lactalbumin and beta-casein
US5807702A (en) * 1995-02-27 1998-09-15 Abbott Laboratories Method for expressing phosphorylated recombinant human β-casein in a bacterial system
EP0812362A1 (en) * 1995-02-27 1997-12-17 Abbott Laboratories A plasmid for expressing modified recombinant proteins in a bacterial system
AU7610496A (en) * 1995-11-06 1997-05-29 Abbott Laboratories A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein

Also Published As

Publication number Publication date
AU1158197A (en) 1997-08-11
ATE246934T1 (de) 2003-08-15
WO1997026320A3 (en) 1997-09-12
DE69629487D1 (de) 2003-09-18
EP0859629B1 (en) 2003-08-13
CA2234680A1 (en) 1997-07-24
EP0859629A2 (en) 1998-08-26
WO1997026320A2 (en) 1997-07-24
JP2000503319A (ja) 2000-03-21

Similar Documents

Publication Publication Date Title
ES2137948T3 (es) Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina.
CA2151604A1 (fr) Application du riluzole dans le traitement de lesions neurologiques liees a des traumatismes
GR3032207T3 (en) 2-Bromomelatonin in the therapy of sleep disorders
HU912064D0 (en) Process for the production of aralyphic n-substituted amino-alcane-phosphine acids and medical preparations containing them
PL312225A1 (en) Novel chemical compounds exhibiting pde iv inhibiting activity
GEP20002300B (en) Purified Forms of Dnase, Method for Its Production, Pharmaceutical Composition and Use Thereof
EP0451750A3 (en) Use of short chain fatty acid containing lipids to maintain gastrointestinal integrity and function in patients
MX9803565A (es) Metodo para inhibir la union de h, influenzae a celulas humanas utilizando beta-caseina humana, fosforilada, recombinante.
MX9803568A (es) Producto para inhibir la union de h. influenzae a celulas humanas.
MY102003A (en) Novel derivatives of 4, 5-dihydrooxazoles, a process for their preparation, and their use.
HUT49284A (en) Process for production of medical compositions applicable "in loco" against androgene hairlessness
ES8707111A1 (es) Procedimiento para obtencion de un preparado farmaceutico para tratamiento terapeutico de enfermedades reumaticas.
MX9605829A (es) Inhibicion de la union del h. influenzae a celulas humanas.
JPS57106618A (en) Anticancer agent consisting of polyprenyl compound
EP0613375A4 (en) PHARMACEUTICAL LYSINE CONTAINING POLYPEPTIDE COMPOSITIONS AND METHOD FOR USE THEREOF.
ES8407043A1 (es) Procedimiento para la fabricacion de derivados aminados de la piridazina substituidos en posicion 6 por un heterociclo o un aliciclo, activos sobre el sistema nervioso central.
MX9605830A (es) Inhibicion de la infeccion de las celulas de mamiferos por el virus sincicial respiratorio.
NZ268039A (en) Use of efaroxan in treating parkinson's disease
NZ329311A (en) use of beta-casein to inhibit infection in mammalian cells by respiratory syncytial virus
MX9701979A (es) Inhibicion de infeccion por rotavirus humano.
DE3480325D1 (en) Pharmaceutical dosage unit
EP0219468A3 (en) 4-methoxy-isophthalic acid derivative having a pharmacological activity in thromboembolic disorders and a process for the preparation thereof
GR3035058T3 (en) Use of derivatives of beta-naphthoquinone for inhibiting platelet aggregation.
Ohgushi et al. Clinical Experience of Disodium Cromoglycate Eye Drops in the Treatment of Allergic Eye Diseases.
MD517G2 (ro) Metodă de tratare a febrei tifoide